ENVELA

Serial Number 77203292
606

Registration Progress

Application Filed
Jun 11, 2007
Under Examination
Sep 2, 2008
Approved for Publication
May 21, 2008
Published for Opposition
Jun 10, 2008
Registered

Trademark Image

ENVELA

Basic Information

Serial Number
77203292
Filing Date
June 11, 2007
Published for Opposition
June 10, 2008
Abandonment Date
October 3, 2011
Drawing Code
3000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Oct 3, 2011
Classes
003 005

Rights Holder

Teikoku Pharma USA, Inc.

03
Address
1718 Ringwood Avenue
San Jose, CA 95131

Ownership History

Teikoku Pharma USA, Inc.

Original Applicant
03
San Jose, CA

Teikoku Pharma USA, Inc.

Owner at Publication
03
San Jose, CA

Legal Representation

Attorney
Bret Field

USPTO Deadlines

All Deadlines Cleared

All 7 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

42 events
Date Code Type Description Documents
Oct 3, 2011 ABN6 S ABANDONMENT - NO USE STATEMENT FILED Loading...
Oct 3, 2011 MAB6 O ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED Loading...
Feb 25, 2011 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Feb 24, 2011 EX5G S SOU EXTENSION 5 GRANTED Loading...
Feb 18, 2011 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 18, 2011 EXT5 S SOU EXTENSION 5 FILED Loading...
Aug 31, 2010 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED Loading...
Aug 30, 2010 EX4G S SOU EXTENSION 4 GRANTED Loading...
Aug 17, 2010 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 17, 2010 EXT4 S SOU EXTENSION 4 FILED Loading...
Mar 5, 2010 EX3G S SOU EXTENSION 3 GRANTED Loading...
Feb 18, 2010 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 18, 2010 EXT3 S SOU EXTENSION 3 FILED Loading...
Sep 4, 2009 EX2G S SOU EXTENSION 2 GRANTED Loading...
Aug 31, 2009 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Aug 31, 2009 EXT2 S SOU EXTENSION 2 FILED Loading...
Mar 11, 2009 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Mar 11, 2009 EX1G S SOU EXTENSION 1 GRANTED Loading...
Feb 24, 2009 EEXT I SOU TEAS EXTENSION RECEIVED Loading...
Feb 24, 2009 EXT1 S SOU EXTENSION 1 FILED Loading...
Sep 2, 2008 NOAM O NOA MAILED - SOU REQUIRED FROM APPLICANT Loading...
Jun 10, 2008 PUBO A PUBLISHED FOR OPPOSITION Loading...
May 21, 2008 NPUB O NOTICE OF PUBLICATION Loading...
May 8, 2008 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
May 8, 2008 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED Loading...
Apr 28, 2008 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Apr 28, 2008 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 28, 2008 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jan 10, 2008 DMCC I DATA MODIFICATION COMPLETED Loading...
Jan 9, 2008 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jan 9, 2008 GNRT O NON-FINAL ACTION E-MAILED Loading...
Jan 9, 2008 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Dec 21, 2007 ALIE A ASSIGNED TO LIE Loading...
Dec 21, 2007 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Dec 21, 2007 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Dec 18, 2007 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Nov 13, 2007 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Sep 20, 2007 CNRT F NON-FINAL ACTION MAILED Loading...
Sep 19, 2007 CNRT R NON-FINAL ACTION WRITTEN Loading...
Sep 17, 2007 DOCK D ASSIGNED TO EXAMINER Loading...
Jun 16, 2007 MDSC O NOTICE OF DESIGN SEARCH CODE MAILED Loading...
Jun 15, 2007 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 003
Cosmetics
First Use Anywhere: 0
First Use in Commerce: 0
Class 005
Prescription and over-the-counter pharmaceutical preparations, namely, transdermal gel formulations, transdermal cream formulations, oral mucous formulations, transdermal patches, dressings and medical adhesive tapes for use in the treatment of cardiovascular conditions, allergies, central nervous system conditions, peripheral nervous system conditions, electrolytic imbalance, caloric imbalance, obesity, vitamin imbalance, gastrointestinal conditions, inflammation, dermatological conditions, infectious diseases, hormonal imbalance, pain, cancer conditions, pulmonary conditions, ophthalmic conditions, musculoskeletal conditions, diabetic conditions, psychosis, senile conditions, dementia, congenital disease conditions, abnormal gene conditions
First Use Anywhere: 0
First Use in Commerce: 0

Additional Information

Design Mark
The mark consists of the wording "ENVELA" with sphere design elements.
Color Claim
Color is not claimed as a feature of the mark.

Classification

International Classes
003 005